AbbVie Inc. reported revenue of $16.99B for the period ended 2026-06-30, +10.2% year on year. Net income was $3.61B, a 21.3% net margin on a 74.7% gross margin. Free cash flow for the period was $3.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $16.99B | +10.2% |
| Gross profit | $12.70B | — |
| Operating income | $6.43B | — |
| Net income | $3.61B | +285.2% |
| Gross margin | 74.7% | Net margin 21.3% |
| Revenue Q/Q | +13.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $4.29B | 25.3% |
| SG&A | $3.63B | 21.4% |
| Tax & other | $2.82B | 16.6% |
| Item | Amount |
|---|---|
| Total assets | $135.12B |
| Total liabilities | $141.00B |
| Shareholders' equity | $-5.89B |
| Equity / assets | -4.4% |
| Operating cash flow | $3.44B |
| Capital expenditure | $0.32B |
| Free cash flow | $3.11B |
| Cash conversion (OCF / net income) | 95% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ACN ・ ADBE ・ AMD ・ AES ・ AFL ・ A ・ APD ・ ABNB ・ AKAM ・ ALB ・ ARE ・ ALGN
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies